Hydrodynamically decoupled nanoprecipitation (HDNP): A multi-stage strategy for supersaturation, controlled delayed nucleation, and stabilization of low LogP poorly-water soluble drugs
Abstract
Poor aqueous solubility is a major drawback of modern drug candidates, affecting their biopharmaceutical performance. Solvent-antisolvent methods involving rapid mixing, such as Flash Nanoprecipitation and Sequential Nanoprecipitation, have advanced the field. However, these remain restricted to compounds with relatively high hydrophobicity (minimum LogP ≥4.5-6). To address this limitation, we introduce Hydrodynamically Decoupled Nanoprecipitation (HDNP). The approach enables decoupling supersaturation, nucleation, and stabilization by controlling the hydrodynamic environments. Dexamethasone (DEX, LogP: 1.83) was used as a model drug. A mechanistically and physics-informed framework was developed, integrating in-line dynamic light scattering for count rate evolution assessment, Computational Fluid Dynamics (CFD), and Design of Experiments for design space establishment. CFD revealed periodic shear stress, high turbulent dissipation rates, and local flow reversal during pulsatile flow under various Womersley numbers, providing favorable hydrodynamic conditions for controlled delayed nucleation. HDNP of DEX successfully produced mainly amorphous nanoparticles (DEX-NPs) stabilized with P407. DEX-NPs exhibited a hydrodynamic diameter of 241 nm, PdI of 0.246, loading efficiency of 77%, enhanced dissolution relative to the micronized drug, and physicochemical stability for at least two weeks. The approach was further evaluated using prednisolone (LogP: 1.62). These findings demonstrate the applicability of HDNP to the nanoprecipitation of the used corticosteroids and highlights its potential as a promising platform for other poorly water-soluble compounds with low LogP.
Related
- Effects of grip strengthening combined with scapular stabilization exercise on shoulder muscle strength and functional outcomes in individuals with subacromial pain syndrome : A randomized controlled trial
- Effect of core stabilization exercises on balance and quality of life among patients with total knee replacement in Gaza Strip, Palestine: a randomized controlled trial
- Photobiomodulation versus stabilization splint, both combined with self-management, for acute temporomandibular myalgia: 48-week outcomes of a partially randomized controlled study
- Physiological and Pathological Responses of Grass Carp (Ctenopharyngodon idella) to Total Dissolved Gas Supersaturation During Exposure and Subsequent Recovery.
- Hsp10 Targets the C-Terminus of α-Synuclein to Inhibit Secondary Nucleation and Remodel Labile Fibrils
BibTeX
@article{castillohenriquez2026hydrodynamically,
title = {{Hydrodynamically decoupled nanoprecipitation (HDNP): A multi-stage strategy for supersaturation, controlled delayed nucleation, and stabilization of low LogP poorly-water soluble drugs}},
author = {Luis Castillo-Henríquez and Clélia Mathieu and Rabah Gahoual and Dhanang Edy Pratama and Cyrille Richard and Nathalie Mignet and José Roberto Vega-Baudrit and Yohann Corvis},
journal = {International Journal of Pharmaceutics: X},
year = {2026},
month = oct,
doi = {10.1016/j.ijpx.2026.100656},
url = {https://hal.science/hal-05794351v1},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Hydrodynamically decoupled nanoprecipitation (HDNP): A multi-stage strategy for supersaturation, controlled delayed nucleation, and stabilization of low LogP poorly-water soluble drugs
AU - Luis Castillo-Henríquez
AU - Clélia Mathieu
AU - Rabah Gahoual
AU - Dhanang Edy Pratama
AU - Cyrille Richard
AU - Nathalie Mignet
AU - José Roberto Vega-Baudrit
AU - Yohann Corvis
PY - 2026
DA - 2026/10/12
JO - International Journal of Pharmaceutics: X
DO - 10.1016/j.ijpx.2026.100656
UR - https://hal.science/hal-05794351v1
AB - Poor aqueous solubility is a major drawback of modern drug candidates, affecting their biopharmaceutical performance. Solvent-antisolvent methods involving rapid mixing, such as Flash Nanoprecipitation and Sequential Nanoprecipitation, have advanced the field. However, these remain restricted to compounds with relatively high hydrophobicity (minimum LogP ≥4.5-6). To address this limitation, we introduce Hydrodynamically Decoupled Nanoprecipitation (HDNP). The approach enables decoupling supersaturation, nucleation, and stabilization by controlling the hydrodynamic environments. Dexamethasone (DEX, LogP: 1.83) was used as a model drug. A mechanistically and physics-informed framework was developed, integrating in-line dynamic light scattering for count rate evolution assessment, Computational Fluid Dynamics (CFD), and Design of Experiments for design space establishment. CFD revealed periodic shear stress, high turbulent dissipation rates, and local flow reversal during pulsatile flow under various Womersley numbers, providing favorable hydrodynamic conditions for controlled delayed nucleation. HDNP of DEX successfully produced mainly amorphous nanoparticles (DEX-NPs) stabilized with P407. DEX-NPs exhibited a hydrodynamic diameter of 241 nm, PdI of 0.246, loading efficiency of 77%, enhanced dissolution relative to the micronized drug, and physicochemical stability for at least two weeks. The approach was further evaluated using prednisolone (LogP: 1.62). These findings demonstrate the applicability of HDNP to the nanoprecipitation of the used corticosteroids and highlights its potential as a promising platform for other poorly water-soluble compounds with low LogP.
SN - 2590-1567
ER -